

Prenatal identification of trisomy 18 (Edwards syndrome)

Thesis submitted for the degree of PhD

Glenn Eric Palomaki

Wolfson Institute of Preventive Medicine

Barts and the London School of Medicine and Dentistry

Queen Mary University of London

14 March 2011

I confirm that the work presented in this thesis is my own.

Glenn Eric Palomaki

Abstract

This thesis is a critical literature review of trisomy 18 (Edwards syndrome), focused on maternal serum and ultrasound markers between 10 and 20 weeks' gestation. Based on comprehensive meta-analyses, existing findings are clarified, new knowledge has emerged, and novel statistical modeling demonstrates clinically useful algorithms to guide screening policies.

Trisomy 18 is, after Down syndrome, the autosomal aneuploidy with the highest birth prevalence, about 2.4/10,000. Only 1 in 5 live born survives to two weeks, with 1 in 20 surviving one year. Strategies for identifying trisomy 18 in early pregnancy rely on re-interpretation of markers measured as part of Down syndrome screening. Diagnosis requires collecting fetal or placental material obtained from an invasive procedure (amniocentesis or a chorionic villus sampling) and subsequent karyotyping or specific aneuploidy testing such as fluorescent in situ hybridization.

The second trimester Triple Test (serum markers alpha-fetoprotein, unconjugated estriol and human chorionic gonadotropin [hCG]) has an 81% detection rate at a 0.4% false positive rate. Adding pregnancy-associated plasma protein-A (PAPP-A) is effective; the detection rate improves to 88% while false positives are reduced to 0.1%. In the first trimester Combined Test, the serum markers (free β hCG and PAPP) in combination with unbiased estimates of ultrasound marker nuchal translucency (NT) thickness, yields detection and false positive rates of 86% and 0.2%, respectively. For these tests, hCG and free β hCG measurements are essentially interchangeable. Combining existing markers from both trimesters into a Full Integrated Test (NT, PAPP-A, and the Triple Test), also yields high performance (91% detection rate at 0.2% false positive rate). Ultrasound markers, apart from NT, are not suitable for routine practice, but some could be used in specialist centers. In the future, testing of circulating cell free nucleic acids in maternal plasma may allow for a reduction in the use of invasive procedures.

Acknowledgments

After being told by colleagues, friends and relatives to pursue an advanced degree for several decades, I must credit Professor Sir Nicholas Wald for providing the final straw that tipped the scale. At his flat in London about four years ago, he reiterated his suggestion but for the first time provided a clear path towards that goal by offering to be an advisor and approaching QMUL administration to answer key questions about a foreign student. Along with Professor Joan Morris, they provided guidance and encouragement. Of specific help was Joan's discussion with me about her non-traditional pursuit of a PhD and her always kind offers to help out with local UK tasks that would have been difficult for me to perform from the US.

On this side of the Atlantic, I was also fortunate that a majority of the monetary requirements were graciously provided by the Board of Directors of the Savjani Institute. The Chair, Jim Haddow, Esq, and members Sue Richards, Jack Canick, and Gopal Savjani were especially important in providing motivation. Within the Institute I received much verbal support from Joanne (e.g., Are you going to work on your thesis this week?), but she was also instrumental in obtaining papers and fighting tirelessly with Word and EndNote on my behalf. Others at the Institute, George Knight, Louis Neveux, Linda Bradley, Ed Kloza all went out of their way to help provide the time to complete my work. It is hard to find the words to express my thanks to Dr. James Haddow. He provided me with my first opportunities to expand my horizons more than 30 years ago and has never stopped. Without his tireless support, this never would have been possible. Lastly, I have to thank my wife Cathie, who hasn't seen me much on the weekends for the last year or so. She never complained about the costs or the time spent. To all of these individuals, and any others I have forgotten to mention, I express my sincere thanks.

Contents

Chapter 1. Historical context and original description	1
Chapter 2. Natural history of trisomy 18.....	4
2.1 The medical disorder: trisomy 18 and its variants	4
2.2 Birth prevalence of trisomy 18	7
2.3 Recurrence risk for trisomy 18.....	11
2.4 Fetal loss during pregnancy	13
2.5 Complications of a trisomy 18 pregnancy.....	17
2.6 Survival after birth	17
2.7 Diagnostic testing for trisomy 18	25
2.8 The child with trisomy 18	27
2.9 Do we 'screen' for trisomy 18?	30
Chapter 3. Second trimester maternal serum markers for trisomy 18.....	31
3.1 Introduction and background	31
3.2 Second trimester AFP measurements.....	38
3.3 Second trimester uE3 measurements	46
3.4 Second trimester hCG measurements	50
3.5 Second trimester free β hCG.....	54
3.6 Second trimester inhibin-A measurements.....	58
3.7 Second trimester PAPP-A measurements	62
3.8 Population parameters for trisomy 18 and unaffected pregnancies	66
3.9 Modeling performance of serum markers.....	72
3.10 Demonstration studies using fixed MoM cut-offs.....	78
3.11 Demonstration studies using trisomy 18 risk.....	80
3.12 Conclusions	85
Chapter 4 First trimester maternal serum markers for trisomy 18	87
4.1 Introduction.....	87
4.2 Common first trimester serum markers	93
4.3 Other first trimester serum markers.....	97
4.4 Population parameters for first trimester serum markers	100
4.5. First trimester markers in trisomy 13 pregnancies.....	111

Chapter 5 First trimester ultrasound markers for trisomy 18	112
5.1 Introduction.....	112
5.2 Nuchal translucency (NT) measurements	114
5.3 Nasal bone	126
5.4 Ductus Venosus	133
5.5 Other ultrasound markers in the first trimester	140
Chapter 6. Combining first trimester markers	143
6.1 Introduction.....	143
6.2 Modeling test performance	143
6.3 Summary of demonstration studies	147
Chapter 7 Integrated testing for trisomy 18	152
7.1 introduction	152
7.2 Modeling serum integrated test performance	153
7.3 Modeling full integrated test performance	157
Chapter 8 Second trimester ultrasound markers for trisomy 18	159
8.1 Introduction.....	159
8.2 Structural anomalies.....	163
8.3 Non-structural Anomalies	181
8.4 Summary of second trimester ultrasound markers.....	222
8.5 Combining second trimester ultrasound markers	224
Chapter 9 Diagnostic testing for trisomy 18	228
9.1 Diagnostic procedures: amniocentesis.....	228
9.2 Diagnostic procedures: chorionic villus sampling (CVS)	231
9.3 Other invasive procedures	234
9.4 Diagnostic testing: karyotype.....	235
9.5 Diagnostic testing: FISH	237
9.6 Diagnostic testing: qfPCR.....	239
9.7 Diagnostic testing: Other methods	241
9.8 Fetal cells and free nucleic acids in maternal circulation.....	243
Chapter 10. Summary	255
References	271

Table of Figures

Chapter 2. Natural history of trisomy 18

Figure 2.2-1.	The birth prevalence of trisomy 18	10
Figure 2.4-1.	Survival of trisomy 18 fetuses during pregnancies	16
Figure 2.6-1.	Survival of live-born infants with trisomy 18.....	21
Figure 2.6-2.	Survival of live-born infants with trisomy 18, stratified by gender	23

Chapter 3. Second trimester maternal serum markers for trisomy 18

Figure 3.1-1.	Sample calculations of an AFP multiple of the median (MoM)	33
Figure 3.1-2.	Overlapping maternal serum AFP measurements in unaffected and Down syndrome pregnancies	35
Figure 3.2-1.	Maternal serum AFP measurements in trisomy 18 pregnancies	40
Figure 3.2-2.	The variance of maternal serum AFP measurements in trisomy 18 pregnancies by year of publication	43
Figure 3.2-3.	Maternal serum AFP measurements in trisomy 18 pregnancies	45
Figure 3.3-1.	Publications reporting maternal serum uE3 measurements in trisomy 18 pregnancies	47
Figure 3.3-2.	Maternal serum uE3 measurements in trisomy 18 pregnancies.....	49
Figure 3.4-1.	Publications reporting maternal serum hCG measurements in trisomy 18 pregnancies.....	51
Figure 3.4-2.	Maternal serum hCG measurements in trisomy 18 pregnancies.....	53
Figure 3.5-1.	Publications reporting maternal serum free β hCG measurements in trisomy 18 pregnancies.....	55
Figure 3.5-2.	Maternal serum free β hCG measurements in trisomy 18 pregnancies ..	57
Figure 3.6-1.	Publications reporting maternal serum inhibin-A measurements in trisomy 18 pregnancies.....	59
Figure 3.6-2.	Maternal serum inhibin-A measurements in trisomy 18 pregnancies	61
Figure 3.7-1.	Publications reporting maternal serum pregnancy associated plasma protein A (PAPP-A) measurements in trisomy 18 pregnancies ..	63
Figure 3.7-2.	Maternal serum PAPP-A measurements in trisomy 18 pregnancies.....	65
Figure 3.8-1.	Overlapping Gaussian curves for six second trimester maternal serum markers in trisomy 18 and unaffected pregnancies.....	68
Figure 3.9-1.	Maternal age distribution in unaffected and trisomy 18 births	73
Figure 3.9-2.	A comparison of two methods of assigning age-associated term risks for trisomy 18	77

Figure 3.11-1.	Publications reporting the results of second trimester trisomy 18 demonstration studies that used patient-specific trisomy 18 risks.....	82
Figure 3.11-2.	The odds of being affected given a positive result (OAPR) for trisomy 18 screening trials using patient-specific risks	84

Chapter 4 First trimester maternal serum markers for trisomy 18

Figure 4.1-1.	Schematic description of the 'ascertainment bias' present in demonstration studies	89
Figure 4.1-2.	Relevant publications for biochemical marker levels in 1 st trimester pregnancies affected with trisomy 18 or trisomy 13.....	92
Figure 4.4-1.	Probability plot for PAPP-A measurements in first trimester trisomy 18 pregnancies from four smaller studies (33 observations)	101
Figure 4.4-2.	Probability plot for free β hCG measurements in first trimester trisomy 18 pregnancies from 10 smaller studies (79 observations)	102
Figure 4.4-3.	Probability plot for intact/total hCG measurements in first trimester trisomy 18 pregnancies from 9 smaller studies (77 observations)	103
Figure 4.4-4.	Forest plots for the first trimester maternal serum markers in trisomy 18 pregnancies.....	105
Figure 4.4-5.	Overlapping Gaussian distributions in unaffected and trisomy 18 pregnancies	110

Chapter 5 First trimester ultrasound markers for trisomy 18

Figure 5.2-1.	Sonographic image of a late first trimester fetal head and thorax showing the correct measurement of nuchal translucency.....	115
Figure 5.2-2.	Hypothetical distribution of NT measurements in trisomy 18 pregnancies in the <u>absence</u> of screening and selective termination.....	119
Figure 5.2-3.	Hypothetical distribution of NT measurements in trisomy 18 pregnancies in the <u>presence</u> of screening and selective termination.....	119
Figure 5.2-4.	The effect of accounting for bias of ascertainment on the NT distribution parameters for trisomy 18	121
Figure 5.2-5.	The effect on the NT distribution parameters for trisomy 18 of including a referral population with increased NT measurements.....	124
Figure 5.3-1.	An ultrasound image showing a fetal head in the late first trimester, along with the identification of the nasal bone.....	127
Figure 5.3-2.	A summary of trisomy 18 (and trisomy 13) observations available to determine associations with absent nasal bone	129

Figure 5.4-1.	Three ductus venosus Doppler waveforms demonstrating differences in the A-wave	133
Figure 5.4-2.	A ductus venosus waveform showing the components needed to compute the pulsatility index for veins (PIV).....	134
Figure 5.4-3.	A summary of trisomy 18 (and trisomy 13) observations available to determine associations with abnormal ductus venosus flow	136

Chapter 6. Combining first trimester markers

Figure 6.3-1.	Summary of publications included in the analysis of demonstration studies for first trimester combined testing for trisomy 18	148
Figure 6.3-2.	Trisomy 18 detection rate and associated false positive rates from eight demonstration studies of first trimester combined test.....	150

Chapter 7. Integrated testing for trisomy 18

Figure 7.2-1.	Correlation between first trimester PAPP-A and second trimester AFP, uE3 and hCG measurements from 12 trisomy 18 pregnancies....	154
---------------	--	-----

Chapter 8. Second trimester ultrasound markers for trisomy 18

Figure 8.2-1.	The included articles of structural anomalies among trisomy 18 fetuses	164
Figure 8.2.1-1.	Forest plot showing the proportion of trisomy 18 pregnancies with open fetal defects	168
Figure 8.2.2-1.	Forest plot showing the proportion of trisomy 18 pregnancies with a major cardiac defect	171
Figure 8.2.3-1.	Forest plot showing the proportion of trisomy 18 pregnancies with hand and foot anomalies	176
Figure 8.2.4-1.	Forest plot showing the proportion of trisomy 18 pregnancies with any structural anomaly	180
Figure 8.3.1-1.	Choroid plexus cyst (CPC)	182
Figure 8.3.1-2.	Sixty-one published studies regarding choroid plexus cysts (CPC) and trisomy 18.....	186
Figure 8.3.1-3.	Relationship between the proportion of women with a CPC identified and year of publication, for studies in the general population	190
Figure 8.3.2-1.	Ultrasound measurement of nuchal skin fold (NSF) thickness.....	201
Figure 8.3.4-1.	Echogenic bowel	210

Figure 8.3.5-1.	Pyelectasis in the early second trimester	212
Figure 8.3.6-1.	Two vessel cord.....	215
Figure 8.3.7-1	Echogenic intra-cardiac focus (EICF).....	218
Figure 8.5-1.	A hypothetical cohort of 17,000 women at high risk for trisomy 18 in the second trimester showing the effect of follow-up ultrasound testing	227

Chapter 9. Diagnostic testing for trisomy 18

Figure 9.1-1.	A diagram showing an ultrasound guided amniocentesis procedure	229
Figure 9.2-1.	A diagram showing an ultrasound guided chorion villus sampling procedure	232
Figure 9.4-1.	A karyotype of a fetus with trisomy 18.....	235
Figure 9.5-1.	Two pictures of interphase cells tested with FISH probes.....	237
Figure 9.6-1.	The result of a normal STR measurement on chromosome 13.....	239
Figure 9.6-2.	Abnormal qfPCR results	240
Figure 9.8.2-1.	Schematic showing how the RNA SNP allelic ratio method of aneuploidy detection	245
Figure 9.8.2-2.	Scatterplot showing the results of an RNA-based SNP allelic ratio test for Down syndrome.....	246
Figure 9.8.2-3.	Scatterplot showing the results of a DNA-based methylation-specific SNP allelic ratio test for trisomy 18.....	248
Figure 9.8.2-4.	A cartoon showing the first two steps in massively parallel sequencing of free DNA in the maternal circulation.....	250
Figure 9.8.2-5.	A cartoon showing the next two steps in massively parallel sequencing of free DNA in the maternal circulation.....	251
Figure 9.8.2-6.	A cartoon showing the last step in massively parallel sequencing of free DNA in the maternal circulation.....	252
Figure 9.8.2-7.	Chromosome 21 z-scores for 28 maternal plasma samples undergoing massively parallel sequencing.....	253

Chapter 10. Summary

Figure 10-1.	Prevalence of trisomy 18 by maternal age, at three selected times in gestation	255
Figure 10-2.	Sequential testing for trisomy 18 in 1,000,000 singleton pregnancies in the general population	267
Figure 10-3.	Serum integrated testing for trisomy 18 in 1,000,000 singleton pregnancies in the general population.....	268

Figure 10-4.	Second trimester testing for trisomy 18 in 1,000,000 singleton pregnancies in the general population.....	269
Figure 10-5.	First trimester 'combined' testing for trisomy 18 in 1,000,000 singleton pregnancies in the general population.....	270

TABLE OF TABLES

Chapter 1. Historical context and original description

Table 1.1-1. Classification of human chromosomes	1
--	---

Chapter 2. Natural history of trisomy 18

Table 2.1-1. Characteristics of infants with trisomy 18	6
Table 2.2-1. Estimated birth prevalence of trisomy 18 in population-based cohorts	9
Table 2.3-1. Trisomy 18 recurrence risk for women diagnosed with a trisomy 18 fetus	12
Table 2.4-1. Spontaneous loss rates for trisomy 18 pregnancies, from specified gestational age to term	15
Table 2.6-1. Summary of studies reporting survival of live-born trisomy 18 infants	19
Table 2.6-2. Survival of live-born trisomy 18 infants stratified by gender	22

Chapter 3. Second trimester maternal serum markers for trisomy 18

Table 3.1-1. Studies of second trimester maternal serum markers and trisomy 18 included for analysis	37
Table 3.2-1. Maternal serum AFP measurements in trisomy 18 and unaffected pregnancies	41
Table 3.3-1. Maternal serum uE3 measurements in trisomy 18 and unaffected pregnancies	48
Table 3.4-1. Maternal serum hCG measurements in trisomy 18 and unaffected pregnancies	52
Table 3.5-1. Maternal serum free β hCG measurements in trisomy 18 and unaffected pregnancies	56
Table 3.6-1. Maternal serum inhibin-A measurements in trisomy 18 and unaffected pregnancies	60
Table 3.7-1. Maternal serum PAPP-A measurements in trisomy 18 and unaffected pregnancies	64
Table 3.8-1. Summary of logarithmic means and standard deviations (SD) for six second trimester maternal serum analytes in trisomy 18 and unaffected pregnancies	67
Table 3.8-2. Summary of reported correlation coefficients between second trimester serum marker in trisomy 18 and in unaffected pregnancies	70
Table 3.9-1. Truncation limits (TL) for maternal serum markers	72

Table 3.9-2. Modeled trisomy 18 detection rates (DR) and false positive rates (FPR) using second trimester maternal serum markers	75
Table 3.9-3. Modeled trisomy 18 detection rates (DR), false positive rates (FPR) and odds of being affected given a positive test result (OAPR) using second trimester maternal serum markers at selected risk cut-off levels	76
Table 3.11-1. Test performance for trisomy 18 in the second trimester using maternal age and measurements of maternal serum AFP, uE3 and hCG to assign patient-specific risks.....	81
Table 3.11-2. Trisomy 18 demonstration studies using patient specific risk	83

Chapter 4 First trimester maternal serum markers for trisomy 18

Table 4.2-1. Summary of biochemical markers for trisomy 18 (and trisomy 13) in the late first trimester having five or more included studies of any size	94
Table 4.3-1. Summary of biochemical markers for trisomy 18 (and trisomy 13) in the late first trimester having fewer than five included studies.....	98
Table 4.4-1. Population parameters for three commonly reported first trimester serum markers of trisomy 18	104
Table 4.4-2. Summary of the correlation coefficients in trisomy 18 pregnancies	107
Table 4.4-3. Summary of population distribution parameters for first trimester maternal serum markers in trisomy 18 and unaffected pregnancies	108

Chapter 5 First trimester ultrasound markers for trisomy 18

Table 5.2-1. Performance of NT measurement in identifying trisomy 18 in the late first trimester, according to one dataset before and after an unbiasing protocol was applied	123
Table 5.3-1. Summary of published studies reporting nasal bone (NB) measurements in unaffected and common trisomic pregnancies between 11 and 14 weeks' gestation	132
Table 5.4-1. Summary of published studies reporting Ductus Venosus (DV) measurements in unaffected and common trisomic pregnancies between 11 and 14 weeks' gestation	139

Chapter 6. Combining first trimester markers

Table 6.2.1. Modeled trisomy 18 detection rates (DR) and false positive rates (FPR) using first trimester maternal serum markers with and without ultrasound measurements of nuchal translucency (NT)	144
Table 6.2-2. Modeled first trimester trisomy 18 screening performance at selected trisomy 18 risk cut-off levels	146
Table 6.3.1. Results of eight demonstration studies of combined testing for trisomy 18	149

Chapter 7. Integrated testing for trisomy 18

Table 7.2-1. <u>Serum integrated</u> testing for trisomy 18: Modeled detection rates (DR) and false positive rates (FPR).....	156
Table 7.3-1. <u>Full integrated</u> testing for trisomy 18: Modeled detection rates (DR) and false positive rates (FPR)	158

Chapter 8. Second trimester ultrasound markers for trisomy 18

Table 8.1-1. Included publications for second ultrasound markers and trisomy 18, excluding those for choroid plexus cysts	161
Table 8.2.1-1. Rates of open fetal defects in trisomy 18 and control pregnancies	167
Table 8.2.2-1. Rates of cardiac defects in trisomy 18 and control pregnancies	172
Table 8.2.3-1. Rates of hand and foot anomalies in trisomy 18 and control pregnancies	175
Table 8.2.4-1. Rate of 'any structural anomaly' in trisomy 18 and control pregnancies ..	179
Table 8.3.1-1. Choroid plexus cysts (CPCs) and trisomy 18: Population based cohort studies	188
Table 8.3.1-2. Choroid plexus cysts (CPCs) and trisomy 18: General population 'screen positive' studies	191
Table 8.3.1-3. Choroid plexus cysts (CPCs) and trisomy 18: High risk case/control and cohort studies.....	194
Table 8.3.1-4. Choroid plexus cysts (CPCs) and trisomy 18: High risk 'screen positive' studies.....	196
Table 8.3.1-5. Choroid plexus cysts (CPCs) and trisomy 18: High risk positive case only studies.....	198
Table 8.3.2-1. Nuchal skin fold thickness (NSF) and trisomy 18	203
Table 8.3.3-1. Fetal long bone (humeral) measurements and trisomy 18	206
Table 8.3.3-2. Fetal long bone (femur) measurements and trisomy 18.....	208

Table 8.3.4-1. Hyperechoic bowel and trisomy 18.....	211
Table 8.3.5-1. Pyelectasis and trisomy 18.....	214
Table 8.3.6-1. Two-vessel cord and trisomy 18.....	217
Table 8.3.7-1. Echogenic intra-cardiac focus (EICF) and trisomy 18	220
Table 8.4-1. Summary of association of second trimester ultrasound markers with trisomy 18.....	223

Chapter 9. Combining first trimester marker for trisomy 18

Chapter 10. Summary

Table 10-1. Prevalence of trisomy 18 by maternal age, at three selected times in gestation.....	256
Table 10-2. Modeled trisomy 18 detection rates (DR) and false positive rates (FPR) using second trimester maternal serum markers at four risk cut-offs	257
Table 10-3. Modeling parameters for four second trimester maternal serum analytes in trisomy 18 and unaffected pregnancies.....	258
Table 10-4. Modeled trisomy 18 detection rates (DR) and false positive rates (FPR) using first trimester serum and ultrasound markers at four risk cut-off levels.....	260
Table 10-5. Modeling parameters for three first trimester maternal serum/ultrasound markers (combined test) in trisomy 18 and unaffected pregnancies	260
Table 10-6. Modeled trisomy 18 detection rates (DR) and false positive rates (FPR) using serum integrated and full integrated testing, at four risk cut-off levels.....	261

Abbreviations

AFP	= alpha-fetoprotein
ASD	= atrial septal defects
CPC	= choroid plexus cysts
CVS	= chorionic villus sampling
DNA	= deoxyribonucleic acid
DR	= detection rate (equivalent to sensitivity)
FISH	= fluorescent in situ hybridization
FPR	= false positive rate (equivalent to 1-specificity)
free β	= the free beta subunit of hCG (hCG is composed of alpha and beta subunits)
hCG	= human chorionic gonadotropin
log	= base 10 logarithm
LR	= likelihood ratio
MoM	= multiple of the median
NB	= nasal bone
NT	= nuchal translucency
OAPR	= odds of being affected given a positive result
ONTD	= open neural tube defect
PAPP-A	= pregnancy associated plasma protein A
PIV	= pulsatility index for veins (in relation to ductus venosus)
PPV	= positive predictive value (%)
qfPCR	= quantitative polymerase chain reaction
RNA	= ribonucleic acid
RR	= relative risk
SD	= standard deviation
SNP	= single nucleotide repeat
STR	= short tandem repeats
uE3	= unconjugated estriol
VSD	= ventricular septal defects